Uses of Placarbo

Placarbo is on the World Health Organization's list of essential medicines. This is a chemotherapy drug used to treat certain types of cancer, such as: ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma.

Placarbo has the main ingredient Carboplatin, which belongs to the group of anti-cancer drugs and acts on the immune system. Placarbo is indicated for use in the following cases:
Treatment of ovarian cancer (from stage Ic to IV, after surgery, recurrence, metastasis after treatment). Treatment of testicular cancer, bladder cancer, advanced and recurrent retinoblastoma in children. Treatment of lung cancer (both small cell lung cancer, both non-small cell lung cancer). Treatment of head and neck cancer. Treatment of Wilms tumor, brain tumor, neuroblastoma. Advanced treatment of non-small cell lung cancer. Treatment of metastatic breast cancer. Treatment of malignant pleural mesothelioma (MPM. Treatment of late stage testicular cancer) Mechanism of action:
Carboplatin is a cytotoxic chemotherapy drug used to treat Carboplatin works by binding to DNA and causing damage that prevents disease-causing cells from reproducing and growing.

How to use: The drug is prepared as a solution for intravenous infusion after dilution. Placarbo is usually given as an intravenous infusion with a duration of 15 minutes or more. The drug can be infused continuously for 24 hours depending on the severity of the disease.
Method of preparation: The drug is diluted with 5% Dextrose or 0.9% NaCl solution until the drug concentration is 0.5 mg/ml.
Note:
Care should be taken in the process of handling the drug, do not let the drug get dirty on the skin. There have been serious cases where the drug got into the eye and led to blindness. When injecting, the drug should be injected into the blood vessel, if injected outside the vessel, it may cause necrosis.
Dosage:
The dose of carboplatin prescribed will be based on clinical response, tolerability, and toxicity. Patients can refer to the following drug dosage:
In the treatment of ovarian cancer in stages III and IV: The starting dose of carboplatin for adults can be used at 300mg/m2. The next dose should be after 4 weeks or so and the dose should be adjusted according to the decrease in platelet count during the previous treatment.
In the treatment of recurrent ovarian cancer: Use a starting dose of 360mg/m2, every 4 weeks. The next times need to adjust the dose of the drug according to the degree of platelet reduction.
For people with kidney disease when using the drug, it is necessary to adjust the dose according to the level of creatinine clearance (ml / min). Specifically:
Creatinine clearance 41-59 using an initial dose of 250 mg/m2 Creatinine clearance between 16-40 using a starting dose of 200 mg/m2 Creatinine clearance less than 15 mL/min: No encourage drug use. Contraindications:
Do not use Placarbo for patients who are allergic to carboplatin or other platinum-containing products. Do not use the drug in patients with impaired hematopoietic system (bone marrow failure) or bleeding. Do not use the drug for patients with severe myelosuppression and severe renal dysfunction. Overdose and treatment:
Manifestations of drug overdose: Carboplatin overdose patients may experience neutropenia and hepatotoxicity. Management: Treat reactions with supportive measures and treat the symptoms experienced by the patient, which may include delaying the next dose.

Carboplatin can cause unwanted effects, as it can interfere with the growth of normal cells as well as cancer cells. Some possible side effects include:
The most common side effects are pain at the injection site, nausea, vomiting, diarrhea, loss of appetite, hair loss and numbness, tingling, burning or pain in the table. hands and feet, increased Bilirubin, visual disturbances and ear infections.
The most serious side effects of carboplatin are:
Bleeding and low blood cells, including decreased red blood cells and platelets, more serious than the patient requiring a blood transfusion during treatment. Patients should tell their doctor immediately if they experience symptoms such as bruising, unusual bleeding, black stools, or blood in the urine. Infections - carboplatin may temporarily lower the number of white blood cells in a person's blood and increase the risk of infection. Experience a potentially fatal allergic reaction- during and after treatment. Hearing loss or tinnitus, increased risk of kidney and liver diseases. If you experience these symptoms, the patient should stop using Placarbo and notify the doctor for appropriate treatment.

During treatment with Placarbo, the patient needs to be closely monitored for health with an oncologist. Tell your doctor if you are having problems such as chickenpox, shingles, hearing problems, infections or kidney disease, because treatment with Carboplatin increases the risk and severity of the disease. importance of these conditions. The drug should be administered under the supervision of an experienced oncologist. Due to the drug is an increased risk of allergic reactions in patients who have previously been exposed to platinum and patients may be at risk of an allergic reaction that may occur within minutes of taking Carboplatin. Dosage should be reduced in patients with bone marrow suppression and impaired renal function, who are anemic. Placarbo should be used with caution in the following cases: Pediatric patients, the elderly, hearing impairments, neurological diseases, neuromuscular diseases, previous use of Cisplatin treatment drugs, concurrent neurotoxic drugs , the drug is toxic on hearing. When patients take high doses of the drug, regular liver function tests should be performed. Use of the drug increases the risk of neuropathy in patients over 65 years of age and in patients who have received prior drug therapy. For pregnant women: Carboplatin should only be used during pregnancy in emergencies when there is no alternative medicine. Because animal studies have shown the drug to be mutagenic, embryotoxic and teratogenic. However, there are currently insufficient data to conduct human pregnancy tests. Therefore, caution must be exercised in this case. For women who are breast-feeding: It is not known whether the drug can be excreted in breast milk. In order to avoid adverse effects affecting the infant, the mother should consult her doctor before taking the drug. treat.

Warfarin: Concomitant use with Placarbo increases the effect of causing bleeding. Phenytoin: Phenytoin concentrations may be decreased when co-administered with Placarbo. When Placarbo is combined with drugs with ototoxic effects such as Ifosfamide, Aminoglycoside and Furosemide, the ototoxic effect of Carboplatin will be increased. Combining Placarbo with other drugs with side effects causing bone marrow depression or radiation therapy will increase blood toxicity. Therefore, in case it is necessary to use the drug, the patient should adjust the dose and duration of use so that the toxicity of the drug can be minimized. Abatacept: The risk or severity of side effects may be increased when Carboplatin is combined with Abatacept. Abciximab: The risk or severity of bleeding may be increased when Abciximab is combined with Carboplatin. Aceclofenac: The risk or severity of nephrotoxicity may be increased when Carboplatin is combined with Aceclofenac. Acetaminophen: Carboplatin may decrease the rate of excretion of Acetaminophen, resulting in higher serum concentrations. Acetazolamide: Acetazolamide may increase the rate of excretion of Carboplatin, which may decrease serum drug concentrations and potentially decrease its effectiveness. Above is all information about Placarbo drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Note, Placarbo is a prescription drug, patients absolutely must not buy and treat at home because they may experience unwanted side effects.